BusinessOtonomy to Report Second Quarter 2017 Financial Results and Provide Corporate UpdateBy Nasdaq OMXJul 27, 2017, 11:30 AM UTC
BusinessOtonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis ExternaBy Nasdaq OMXJul 18, 2017, 11:30 AM UTC
BusinessOtonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy TubesBy Nasdaq OMXJun 22, 2017, 11:30 AM UTC
BusinessOtonomy to Host Key Opinion Leader Meeting for Investors on Ménière's DiseaseBy Nasdaq OMXJun 20, 2017, 11:30 AM UTC
BusinessOtonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual MeetingBy Nasdaq OMXMay 12, 2017, 11:31 AM UTC
BusinessOtonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual MeetingBy Nasdaq OMXMay 12, 2017, 11:30 AM UTC
BusinessOtonomy to Present at the Bank of America Merrill Lynch Health Care ConferenceBy Nasdaq OMXMay 10, 2017, 8:07 PM UTC
BusinessOtonomy to Present at the Bank of America Merrill Lynch Health Care ConferenceBy Nasdaq OMXMay 10, 2017, 8:07 PM UTC
